Regeneron Pharmaceuticals’ (REGN) “Underperform” Rating Reaffirmed at Bank of America

Bank of America reiterated their underperform rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a report published on Tuesday morning, Marketbeat Ratings reports. Bank of America currently has a $565.00 price target on the biopharmaceutical company’s stock.

Other analysts also recently issued research reports about the company. Cantor Fitzgerald restated a “neutral” rating and set a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Evercore ISI reduced their price objective on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Leerink Partners reaffirmed a “market perform” rating and set a $1,077.00 target price (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. BMO Capital Markets reduced their price target on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a report on Friday, November 1st. Finally, Royal Bank of Canada dropped their price objective on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $1,099.90.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $778.50 on Tuesday. The firm has a market capitalization of $85.55 billion, a PE ratio of 19.27, a PEG ratio of 3.00 and a beta of 0.08. Regeneron Pharmaceuticals has a 1 year low of $735.95 and a 1 year high of $1,211.20. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The firm’s fifty day simple moving average is $871.59 and its 200 day simple moving average is $1,010.52.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. DGS Capital Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 13.8% during the third quarter. DGS Capital Management LLC now owns 429 shares of the biopharmaceutical company’s stock valued at $451,000 after acquiring an additional 52 shares during the period. Oddo BHF Asset Management Sas acquired a new position in Regeneron Pharmaceuticals during the 3rd quarter valued at about $1,598,000. American Trust bought a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at about $600,000. Synovus Financial Corp grew its position in shares of Regeneron Pharmaceuticals by 3.4% during the 3rd quarter. Synovus Financial Corp now owns 1,881 shares of the biopharmaceutical company’s stock worth $1,977,000 after buying an additional 61 shares during the period. Finally, Tidal Investments LLC raised its stake in shares of Regeneron Pharmaceuticals by 8.7% during the third quarter. Tidal Investments LLC now owns 6,350 shares of the biopharmaceutical company’s stock worth $6,675,000 after buying an additional 510 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.